von Minckwitz, Gunter <br/><br/>
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Apr 2009 
 - 1999-2006 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2008.19.6618  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Capecitabine<br/>Chemotherapy, Adjuvant<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Female<br/>Fluorouracil--administration & dosage<br/>Follow-Up Studies<br/>Humans<br/>Immunoenzyme Techniques<br/>International Agencies<br/>Middle Aged<br/>Neoplasm Staging<br/>Prognosis<br/>Receptor, ErbB-2--metabolism<br/>Risk Factors<br/>Survival Rate<br/>Time Factors<br/>Trastuzumab<br/>Treatment Outcome